Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CAF-1 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9UIV1 |
|---|---|
| Clone Names | 80821005 |
| Gene ID | 29883 |
|---|---|
| Other Names | CCR4-NOT transcription complex subunit 7, BTG1-binding factor 1, CCR4-associated factor 1, CAF-1, Caf1a, CNOT7, CAF1 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | CNOT7 |
|---|---|
| Synonyms | CAF1 |
| Function | Has 3'-5' poly(A) exoribonuclease activity for synthetic poly(A) RNA substrate (PubMed:20634287, PubMed:31439799, PubMed:19276069). Its function seems to be partially redundant with that of CNOT8 (PubMed:19605561). Catalytic component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation (PubMed:20634287, PubMed:31439799, PubMed:19276069). During miRNA- mediated repression the complex seems also to act as translational repressor during translational initiation (PubMed:20065043). Additional complex functions may be a consequence of its influence on mRNA expression (PubMed:23236473, PubMed:19276069). Associates with members of the BTG family such as TOB1 and BTG2 and is required for their anti- proliferative activity (PubMed:23236473, PubMed:19276069). |
| Cellular Location | Nucleus. Cytoplasm, P-body {ECO:0000250|UniProtKB:Q60809}. Cytoplasm, Cytoplasmic ribonucleoprotein granule. Note=NANOS2 promotes its localization to P-body (By similarity). Recruited to cytoplasmic ribonucleoprotein membraneless compartments by CAPRIN1, promoting deadenylation of mRNAs (PubMed:31439799) {ECO:0000250|UniProtKB:Q60809, ECO:0000269|PubMed:31439799} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene binds to ananti-proliferative protein, B-cell translocation protein 1, whichnegatively regulates cell proliferation. Binding of the twoproteins, which is driven by phosphorylation of theanti-proliferative protein, causes signaling events in celldivision that lead to changes in cell proliferation associated withcell-cell contact. The protein has both mouse and yeast orthologs.Alternate splicing of this gene results in two transcript variantsencoding different isoforms.
References
Lau, N.C., et al. Biochem. J. 422(3):443-453(2009)Aslam, A., et al. Mol. Biol. Cell 20(17):3840-3850(2009)Miyasaka, T., et al. Cancer Sci. 99(4):755-761(2008)Nishida, K., et al. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 63 (PT 12), 1061-1063 (2007) :Robin-Lespinasse, Y., et al. J. Cell. Sci. 120 (PT 4), 638-647 (2007) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
